Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

'KPop Demon Hunters' join Bad Bunny on 'SNL' 'SNL' cold open spoofs Pete Hegseth’s military meeting 'SNL' cold open mocks Pam Bondi's Senate hearing What’s the solution for someone trying to sober up, ...

Eli Lilly has committed to setting a new standard for on-screen representation of common chronic diseases, and it walked the walk with its recent sponsorship of a segment on “Project Runway.” In the ...

Global entertainer Lilly Singh has come aboard the short film “Holy Curse” in an executive producer capacity, backing director Snigdha Kapoor’s acclaimed drama about gender identity and cultural ...

Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...

The company's multibillion-dollar investments in manufacturing in the U.S. are likely to be warmly welcomed by the Trump administration. Eli Lilly's management has already committed to taking action ...

The social media star and advocate — who shares her experience with arteriovenous malformation (AVM) — hit the catwalk in a stunning tulle gown Starr Bowenbank is the Style Editor at PEOPLE. She ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

Corey Dambacher was working in Oregon when he discovered a type of ribonucleic acid capable of creating unique types of proteins that express themselves on the surfaces of cancer cells. It’s just the ...

Of the title character in “Lost Evangeline,” it is said she “lived a great life of the imagination.” You could say the same about Evangeline’s creator, Kate DiCamillo. The beloved, Minneapolis-based ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly closed the trial on ...

Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a single patient, citing “strategic business reasons.” The study was designed to test bimagrumab, an asset Lilly acquired in ...